Mildred Sergon
Overview
Explore the profile of Mildred Sergon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haggenmuller S, Wies C, Abels J, Winterstein J, Heinlein L, Nogueira Garcia C, et al.
Nat Commun
. 2025 Jan;
16(1):789.
PMID: 39824857
Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images and clinical metadata of 792...
2.
Heinlein L, Maron R, Hekler A, Haggenmuller S, Wies C, Utikal J, et al.
Commun Med (Lond)
. 2024 Sep;
4(1):177.
PMID: 39256516
Background: Early detection of melanoma, a potentially lethal type of skin cancer with high prevalence worldwide, improves patient prognosis. In retrospective studies, artificial intelligence (AI) has proven to be helpful...
3.
Haggenmuller S, Maron R, Hekler A, Krieghoff-Henning E, Utikal J, Gaiser M, et al.
J Am Acad Dermatol
. 2024 Apr;
91(2):366-370.
PMID: 38670313
No abstract available.
4.
Haggenmuller S, Schmitt M, Krieghoff-Henning E, Hekler A, Maron R, Wies C, et al.
JAMA Dermatol
. 2024 Feb;
160(3):303-311.
PMID: 38324293
Importance: The development of artificial intelligence (AI)-based melanoma classifiers typically calls for large, centralized datasets, requiring hospitals to give away their patient data, which raises serious privacy concerns. To address...
5.
Hekler A, Maron R, Haggenmuller S, Schmitt M, Wies C, Utikal J, et al.
J Am Acad Dermatol
. 2024 Jan;
90(5):1028-1031.
PMID: 38199280
No abstract available.
6.
Dinter L, Karitzky P, Schulz A, Wurm A, Mehnert M, Sergon M, et al.
Int J Cancer
. 2023 Dec;
154(6):1057-1072.
PMID: 38078628
About 25% of melanoma harbor activating NRAS mutations, which are associated with aggressive disease therefore requiring a rapid antitumor intervention. However, no efficient targeted therapy options are currently available for...
7.
Krocher A, Folprecht G, Winzer R, Sergon M, Bornhauser M, Kotzerke J, et al.
Case Rep Oncol
. 2023 Oct;
16(1):1166-1171.
PMID: 37900794
Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (Lu) - DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and...
8.
Maron R, Hekler A, Haggenmuller S, von Kalle C, Utikal J, Muller V, et al.
Eur J Cancer
. 2022 Aug;
173:307-316.
PMID: 35973360
Background: Image-based cancer classifiers suffer from a variety of problems which negatively affect their performance. For example, variation in image brightness or different cameras can already suffice to diminish performance....
9.
Pietzsch L, Korholz J, Boschann F, Sergon M, Dorjbal B, Yee D, et al.
Front Immunol
. 2022 Jun;
13:878989.
PMID: 35651609
Background: Atopic dermatitis (AD) affects up to 25% of children and 10% of adults in Western countries. When severe or recurrent infections and exceedingly elevated serum IgE levels occur in...
10.
Hauser K, Kurz A, Haggenmuller S, Maron R, von Kalle C, Utikal J, et al.
Eur J Cancer
. 2022 Apr;
167:54-69.
PMID: 35390650
Background: Due to their ability to solve complex problems, deep neural networks (DNNs) are becoming increasingly popular in medical applications. However, decision-making by such algorithms is essentially a black-box process...